Analysis Tools
integument
|
• 7-10 days following 4-hydroxytamoxifen (4-HT) treatment, all mice show expansion of highly pigmented cells that develop into pigmented malignant lesions in locations of 4-HT administration such as the face, flank, or tail skin
• pigmented melanoma cells are seen throughout the dermis and subcutis of 4-HT treated mice and show pagetoid spread into the epidermis
• lesions in 4-HT treated mice progress rapidly to advanced malignancy such that all mice require euthanasia 25-50 days following 4-HT administration
• treatment of 4-HT treated mice with the MEK1/2 inhibitor PD325901 or the mTorc1 inhibitor rapamycin inhibits melanoma formation
• mice in which drug treatment is ceased subsequently develop malignant melanoma
• mice treated once with PD325901 to prevent melanoma remain sensitive to the anti-melanoma action of a second round of PD325901 administration
• treatment of melanoma bearing mice with either PD325901 or rapamycin inhibits further tumor growth but has little or no effect on tumor regression
• treatment of melanoma bearing with both PD325901 or rapamycin results in a 20% reduction in tumor size
|
neoplasm
|
• 7-10 days following 4-hydroxytamoxifen (4-HT) treatment, all mice show expansion of highly pigmented cells that develop into pigmented malignant lesions in locations of 4-HT administration such as the face, flank, or tail skin
• pigmented melanoma cells are seen throughout the dermis and subcutis of 4-HT treated mice and show pagetoid spread into the epidermis
• lesions in 4-HT treated mice progress rapidly to advanced malignancy such that all mice require euthanasia 25-50 days following 4-HT administration
• treatment of 4-HT treated mice with the MEK1/2 inhibitor PD325901 or the mTorc1 inhibitor rapamycin inhibits melanoma formation
• mice in which drug treatment is ceased subsequently develop malignant melanoma
• mice treated once with PD325901 to prevent melanoma remain sensitive to the anti-melanoma action of a second round of PD325901 administration
• treatment of melanoma bearing mice with either PD325901 or rapamycin inhibits further tumor growth but has little or no effect on tumor regression
• treatment of melanoma bearing with both PD325901 or rapamycin results in a 20% reduction in tumor size
|
|
• spread of melanoma is seen into the regional draining lymph nodes in 100% of mice and to the lungs in some cases
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| skin melanoma | DOID:8923 |
OMIM:608035 OMIM:612263 |
J:151023 | |
